Formulation

March 03, 2021

Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.

March 02, 2021

FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.

February 03, 2021

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

February 03, 2021

Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.

February 03, 2021

Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.

January 03, 2021

The right partner can help companies overcome key formulation challenges for biologic drugs.

December 16, 2020

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

December 10, 2020

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.

December 08, 2020

A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.

December 03, 2020

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.